Insightec Overview
INSIGHTEC is a global healthcare company creating the next generation of patient care by realizing the therapeutic power of acoustic energy. The company's Exablate Neuro platform focuses sound waves, safely guided by MRI, to provide tremor treatment to patients with medication-refractory Essential Tremor and Parkinson's Disease. INSIGHTEC obtained FDA approval for its technology in 2016 and 2018. Also received FDA approval and CE Mark of its Exablate Prime system. It is continuously investing in and expanding its current and investigational applications, ranging from functional neurosurgery to oncology and gynecology.
Cumulative Funding Raised Over Time ($)
$136.0MApr 2021
$166.9MDec 2012
$225.9MDec 2014
$375.9MDec 2017
$397.9MJan 2016
$547.9MJun 2024
$577.9MNov 2007
$592.9MSep 2006
$792.9MSep 2022
Latest News
growth-positive
/PRNewswire/ -- Insightec, a global healthcare innovator pioneering the use of focused ultrasound to transform patient care, today announced that Lord Julian...
Insightec, a global healthcare company, is making strides in treating essential tremor (ET) with its MR-guided focused ultrasound technology. Lord Julian Fellowes, known for creating Downton Abbey, underwent this treatment and experienced significant improvement in his tremor, which had impacted his ability to write. The treatment, which is incisionless and safe, has been used on over 25,000 patients worldwide, showing a 73.1% average improvement in tremor severity over five years. Insightec aims to raise awareness about ET and promote broader access to innovative treatments. The companys Exablate Neuro platform is also exploring applications for Parkinsons disease, in collaboration with academic and medical institutions.
growth-positive
/CNW/ -- Insightec, a global healthcare innovator dedicated to using focused ultrasound to transform patient care, announced today that the U.S. Food and Drug...
Insightec, a global healthcare innovator, has received FDA approval for the expanded use of its Exablate Neuro platform for staged bilateral pallidothalamic tractotomy treatment in patients with advanced Parkinsons disease. This approval allows for comprehensive bilateral treatment, offering new hope to over 50,000 patients suffering from severe motor symptoms. The Exablate Neuro platform uses focused ultrasound guided by MRI, providing a non-invasive treatment option with a lower risk profile compared to traditional surgeries. The approval follows a successful clinical trial conducted across multiple centers in the U.S., Europe, and Asia. Insightec plans a limited launch of the bilateral procedure in select centers by 2025, aiming to establish reimbursement pathways for broader access.
Product StageFDA approved/pending approval
growth-positive
גידול של 20% בהכנסות אינסייטק - Techtime - חדשות אלקטרוניקה והייטק
Insightec, a medical device company, reported a 20% increase in revenue for Q1 2025, reaching $16.8 million compared to $14 million in the same quarter last year. Despite the revenue growth, the company continues to incur losses, with a net loss of $16.4 million, an improvement from the $26.2 million loss a year ago. Insightec recently completed a significant capital raise, which helped alleviate its financial deficit, leaving it with $148 million in cash reserves. The company has developed a non-invasive treatment system for essential tremor and Parkinsons symptoms using focused ultrasound technology guided by MRI. This system allows for precise treatment without surgery or incisions, performed while the patient is fully conscious.
Investment
growth-positive
/PRNewswire/ -- Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to...
Charles River Laboratories International, Inc. and Insightec have announced a five-year strategic collaboration to advance therapeutic applications in neuroscience using focused ultrasound technology. This partnership aims to enhance drug discovery and preclinical development by providing Charles Rivers clients with access to Insightecs low-frequency ultrasound platform, which can non-invasively disrupt the blood-brain barrier for targeted drug delivery. The collaboration is expected to accelerate the development of groundbreaking therapies for neurological conditions, including Parkinsons and Alzheimers diseases. Both companies believe this integration will revolutionize CNS drug delivery and improve patient outcomes globally.
Partners
growth-positive
/PRNewswire/ -- Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced the appointment of Jake...
Insightec, a global healthcare company specializing in focused ultrasound technology, has appointed Jake Ghannam as its new Chief Commercial Officer. Ghannam, who has a strong background in strategic planning and business development from his time at Medtronic and GE HealthCare, will lead Insightecs commercial operations and market strategies. His appointment is expected to drive growth and innovation within the company, aligning with Insightecs mission to advance patient care through cutting-edge technologies. Insightecs Exablate Neuro platform is currently used for treating essential tremor and Parkinsons disease, with ongoing research for future applications in neuroscience.
Management Changes
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $592.9M |
| Last funding | $150M |
| Stage | G |
| Rounds | 9 |
| Investors | 18 |
Team Members
4
Employees: 201-500
Web & Social Links
| Website | insightec.com |
| Careers | Careers page |
Locations
Nahum Het St 5, Tirat Carmel, Israel
Dallas, TX, USA
Munich, Germany
Miami, FL, USA
Photos & Videos
2 item(s)
Insightec Business
Business models
B2B
Product stage
Released
Employees
201-500
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Simulation & ImagingUltrasoundPlatforms & InterfacesSoftwareTags (18)
monitoringmedical-devicesoncologyhospitalsnon-invasivegynecologycancerunicorn-2020urologyneurologywomen-healthultrasoundparkinsonneurosurgeryhardwaresoftware-applicationsbonetreatmentsGeographic Markets
AsiaJapanUnited StatesEuropeChinaInsightec Financials
$592.9M
Total funding
Undisclosed
Capital raised
$150M
Last funding
G
Funding stage
9
Total rounds
18
Investors
Cumulative Funding Raised Over Time ($)
$136.0MApr 2021
$166.9MDec 2012
$225.9MDec 2014
$375.9MDec 2017
$397.9MJan 2016
$547.9MJun 2024
$577.9MNov 2007
$592.9MSep 2006
$792.9MSep 2022
Private Equity Funding
G Round
Jun 2024
$150M
Fidelity Management & Research Company (Lead)
,
Nexus NeuroTech Ventures, OurCrowd, Peregrine Ventures, Ally Bridge Group, Catalio Capital Management
Debt Financing
Sep 2022
$200M
Perceptive Advisors (Lead)
F Round
Apr 2021
$136M
Koch Disruptive Technologies (Lead)
,
Happiness Capital, OurCrowd
E Round
Dec 2017
$150M
Elbit Imaging, OurCrowd, Koch Disruptive Technologies, GE Healthcare, Focus Holdings, Exigent Capital Group, Medtech Advisors, York Capital Management
D Round
Jan 2016
$22M
Medtech Advisors, Elbit Imaging, York Capital Management, GE Healthcare
D Round
Dec 2014
$59M
Medtech Advisors, York Capital Management, GEOC, Elbit Imaging, GE Healthcare
C Round
Dec 2012
$30.9M
GE Healthcare
A Round
Nov 2007
$30M
Medtech Advisors, Elbit Imaging, GE Capital
Undisclosed Round
Sep 2006
$15M
Elbit Imaging, General Electric
Insightec Lifecycle
Cumulative Funding Raised Over Time
$136.0MApr 2021
$166.9MDec 2012
$225.9MDec 2014
$375.9MDec 2017
$397.9MJan 2016
$547.9MJun 2024
$577.9MNov 2007
$592.9MSep 2006
$792.9MSep 2022
All Events
G Round
Jun 2024
$150M
Fidelity Management & Research Company (Lead)
,
Nexus NeuroTech Ventures, OurCrowd, Peregrine Ventures, Ally Bridge Group, Catalio Capital Management
Debt Financing
Sep 2022
$200M
Perceptive Advisors (Lead)
F Round
Apr 2021
$136M
Koch Disruptive Technologies (Lead)
,
Happiness Capital, OurCrowd
E Round
Dec 2017
$150M
Elbit Imaging, OurCrowd, Koch Disruptive Technologies, GE Healthcare, Focus Holdings, Exigent Capital Group, Medtech Advisors, York Capital Management
D Round
Jan 2016
$22M
Medtech Advisors, Elbit Imaging, York Capital Management, GE Healthcare
D Round
Dec 2014
$59M
Medtech Advisors, York Capital Management, GEOC, Elbit Imaging, GE Healthcare
C Round
Dec 2012
$30.9M
GE Healthcare
A Round
Nov 2007
$30M
Medtech Advisors, Elbit Imaging, GE Capital
Undisclosed Round
Sep 2006
$15M
Elbit Imaging, General Electric
Insightec News
52 articles
growth-positive
/PRNewswire/ -- Insightec, a global healthcare innovator pioneering the use of focused ultrasound to transform patient care, today announced that Lord Julian...
Insightec, a global healthcare company, is making strides in treating essential tremor (ET) with its MR-guided focused ultrasound technology. Lord Julian Fellowes, known for creating Downton Abbey, underwent this treatment and experienced significant improvement in his tremor, which had impacted his ability to write. The treatment, which is incisionless and safe, has been used on over 25,000 patients worldwide, showing a 73.1% average improvement in tremor severity over five years. Insightec aims to raise awareness about ET and promote broader access to innovative treatments. The companys Exablate Neuro platform is also exploring applications for Parkinsons disease, in collaboration with academic and medical institutions.
growth-positive
/CNW/ -- Insightec, a global healthcare innovator dedicated to using focused ultrasound to transform patient care, announced today that the U.S. Food and Drug...
Insightec, a global healthcare innovator, has received FDA approval for the expanded use of its Exablate Neuro platform for staged bilateral pallidothalamic tractotomy treatment in patients with advanced Parkinsons disease. This approval allows for comprehensive bilateral treatment, offering new hope to over 50,000 patients suffering from severe motor symptoms. The Exablate Neuro platform uses focused ultrasound guided by MRI, providing a non-invasive treatment option with a lower risk profile compared to traditional surgeries. The approval follows a successful clinical trial conducted across multiple centers in the U.S., Europe, and Asia. Insightec plans a limited launch of the bilateral procedure in select centers by 2025, aiming to establish reimbursement pathways for broader access.
Product StageFDA approved/pending approval
growth-positive
גידול של 20% בהכנסות אינסייטק - Techtime - חדשות אלקטרוניקה והייטק
Insightec, a medical device company, reported a 20% increase in revenue for Q1 2025, reaching $16.8 million compared to $14 million in the same quarter last year. Despite the revenue growth, the company continues to incur losses, with a net loss of $16.4 million, an improvement from the $26.2 million loss a year ago. Insightec recently completed a significant capital raise, which helped alleviate its financial deficit, leaving it with $148 million in cash reserves. The company has developed a non-invasive treatment system for essential tremor and Parkinsons symptoms using focused ultrasound technology guided by MRI. This system allows for precise treatment without surgery or incisions, performed while the patient is fully conscious.
Investment
growth-positive
/PRNewswire/ -- Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to...
Charles River Laboratories International, Inc. and Insightec have announced a five-year strategic collaboration to advance therapeutic applications in neuroscience using focused ultrasound technology. This partnership aims to enhance drug discovery and preclinical development by providing Charles Rivers clients with access to Insightecs low-frequency ultrasound platform, which can non-invasively disrupt the blood-brain barrier for targeted drug delivery. The collaboration is expected to accelerate the development of groundbreaking therapies for neurological conditions, including Parkinsons and Alzheimers diseases. Both companies believe this integration will revolutionize CNS drug delivery and improve patient outcomes globally.
Partners
growth-positive
/PRNewswire/ -- Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced the appointment of Jake...
Insightec, a global healthcare company specializing in focused ultrasound technology, has appointed Jake Ghannam as its new Chief Commercial Officer. Ghannam, who has a strong background in strategic planning and business development from his time at Medtronic and GE HealthCare, will lead Insightecs commercial operations and market strategies. His appointment is expected to drive growth and innovation within the company, aligning with Insightecs mission to advance patient care through cutting-edge technologies. Insightecs Exablate Neuro platform is currently used for treating essential tremor and Parkinsons disease, with ongoing research for future applications in neuroscience.
Management Changes
growth-positive
/CNW/ -- Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced the appointment of Jake...
Insightec, a global healthcare company specializing in focused ultrasound technology, has appointed Jake Ghannam as its new Chief Commercial Officer. Ghannam, who has a strong background in strategic planning and business development from his previous roles at Medtronic and GE HealthCare, will lead Insightecs commercial operations and market strategies. His appointment is expected to drive growth and innovation, aligning with Insightecs mission to transform patient care through advanced technologies. The company is headquartered in Haifa, Israel, and Miami, with additional offices in Dallas, Shanghai, and Tokyo.
Management Changes
growth-positive
INSIGHTEC ANNOUNCES $150M FINANCING TO FUND CONTINUED GROWTH
Insightec, a global healthcare company, has raised $150 million in equity financing. The round was led by Fidelity Management & Research Company and co-led by Nexus Neurotech Ventures and Ally Bridge Group. The funds will be used to expand incisionless neurosurgery to patients suffering from movement disorders and to make strategic investments in new indications. Insightecs technology has been used in nearly 20,000 commercial applications and is currently FDA approved as an immediate treatment for patients suffering from essential tremor and Parkinsons disease.
InvestmentExpand
growth-positive
Insightec device aids Alzheimer's drug delivery - study
A study conducted by the WVU Rockefeller Neuroscience Institute found that a device produced by Israeli company Insightec, in combination with a drug for treating Alzheimers Disease, facilitated the opening of the blood-brain barrier, enabling the drug to be delivered more effectively. The drug used in the trial was Aduhelm, a previous drug from Biogen and Eisai. The study indicates a potential future use of Insightecs technology in the Alzheimers market. Insightec has raised around $550 million to date and has brought several focused ultrasound products to market.
InvestmentPartners
growth-positive
POTENTIAL BREAKTHROUGH FOR ALZHEIMER'S TREATMENT: FOCUSED ULTRASOUND COMBINED WITH MONOCLONAL ANTIBODIES MAY SLOW DISEASE PROGRESSION
Insightec, a global healthcare company, has announced a promising clinical study in the treatment of Alzheimers disease using focused ultrasound (FUS) technology. The study, conducted with WVU Rockefeller Neuroscience Institute (RNI), found that combining the use of focused ultrasound to open the blood-brain barrier with the delivery of a systemic monoclonal antibody infusion can enhance the removal of cerebral beta-amyloid, a hallmark of Alzheimers disease. This innovative treatment approach shows promise in enhancing targeted drug delivery in Alzheimers disease and other neurological conditions.
PartnersExpand
growth-negative
Medical device company Insightec laying off 100 employees, 20% of workforce | CTech
Insightec, an Israeli medical device company, is laying off 100 employees, representing 20% of its workforce. The layoffs will occur at the companys headquarters in Israel and other locations worldwide. Insightec has developed a platform that uses sound waves, guided by MRI, to treat patients with medication-refractory essential tremor and Parkinsons disease. The company, managed by founder Dr. Kobi Vortman, is controlled by the Koch family. Two years ago, Insightec was in talks to merge with a SPAC at a value of $1.9 billion, but the deal fell through. In September, Insightec secured a credit facility for up to $200 million with affiliates of existing shareholders Perceptive Advisors and Community Fund.
LayoffsInvestment
growth-positive
INSIGHTEC ANNOUNCES NEW CATEGORY I CPT® CODE FROM AMA FOR NEURO PROCEDURES USING MR-GUIDED FOCUSED ULTRASOUND
Insightec, a global healthcare company, has announced that the American Medical Association (AMA) has approved their application to establish a new Category I Current Procedural Terminology (CPT®) code for MR-guided focused ultrasound (MRgFUS) ablation of neurological targets. This approval is expected to facilitate standardized reimbursement for US physicians using this technology, and is seen as a significant milestone for the company. The new code is also expected to expand access to focused ultrasound for US patients. The new CPT® code will be included in the next CPT® codebook and is expected to be effective from January 1, 2025.
CustomersPartnersExpand
Growth-Positive
Insightec Receives CE Mark Approval to Treat Essential Tremor Patients' Second Side, Expanding Treatment Options for People Living with Essential Tremor
Insightec, a global healthcare company specializing in MR-guided focused ultrasound (MRgFUS), has received additional CE mark approval for the treatment of essential tremor using its Exablate Neuro platform. The approval allows patients to have their second side treated at least nine months after treatment of the first side, potentially providing tremor relief on both sides of the body. The Insightec-sponsored study showed a highly significant reduction in tremor following treatment of the second side, with results sustained through at least six months of follow-up.
Expand
growth-positive
Insightec receives US FDA approval to treat essential tremor patients' second side - NeuroNews International
Insightec has received FDA approval for the treatment of essential tremor using its Exablate Neuro platform. The approval allows patients to have their second side treated at least nine months after treatment of the first side. A study sponsored by Insightec showed a significant reduction in tremor following treatment of the second side, with sustained results for at least six months. There was also an improvement in functional disability. The approval is seen as an important milestone for Insightec in expanding treatment options for people with essential tremor.
Customers
growth-positive
Insightec Receives FDA Approval to Treat Essential Tremor Patients' Second Side, Expanding Total Available Market in United States
Insightec has received an additional FDA approval for the treatment of essential tremor using its Exablate Neuro platform. The approval allows appropriate patients to have their second side treated at least nine months after treatment of the first side. The study showed a significant reduction in tremor following treatment of the second side, with sustained results for at least six months. There was also a significant improvement in functional disability. The approval is seen as an important milestone for Insightec in expanding treatment options for people with essential tremor.
Customers
growth-positive
Insightec Announces Financing up to $200 Million to Fund Continued Growth
Insightec, a global healthcare company, has signed a credit facility for up to $200 million with affiliates of existing shareholders Perceptive Advisors and Community Fund. The financing will support the companys efforts in driving adoption of incisionless neurosurgery and advancing innovation in neuro-oncology and other neurological conditions. Perceptive Advisors expressed excitement about expanding its partnership with Insightec and supporting the commercialization and expansion of its incisionless platform. The credit facility is interest-only for five years and matures on August 31, 2027. Insightec is focused on growing its customer base of medical centers across the Americas, Europe, and Asia.
Investment
growth-positive
INSIGHTEC RECEIVES FDA IDE APPROVAL FOR PROSTATE CANCER COMPARATIVE STUDY USING HIGH INTENSITY FOCUSED ULTRASOUND TECHNOLOGY
Insightec has received FDA approval for a clinical comparative study of the Exablate Prostate system used to treat prostate cancer. The study will evaluate the safety and efficacy of focal treatment using high intensity focused ultrasound compared to active surveillance. The Exablate Prostate system uses sound waves to destroy targeted tissue in the prostate, and the treatment is performed under MRI guidance. The study aims to demonstrate the clinical benefits of the system and improve quality of life outcomes for patients. Insightec previously conducted a clinical trial for the system, which reported minimal damage to adjacent structures and low rates of impact on potency and continence. The Exablate Prostate system received FDA clearance in November 2021 and was used to treat its first US commercial patient in January 2022.
Customers
growth-positive
INSIGHTEC RECEIVES FDA IDE APPROVAL AND "BREAKTHROUGH" DESIGNATION FOR NSCLC BRAIN METS STUDY AND IDE APPROVAL FOR LIQUID BIOPSY STUDY
Insightec, a global healthcare company, has received FDA approval for two pivotal investigational device exemptions (IDE) for its Exablate Neuro system. The approvals are for primary non-small cell lung cancer (NSCLC) that has metastasized to the brain in conjunction with standard-of-care Keytruda, and for enhanced efficacy of liquid biopsy for recurrence monitoring of patients with primary brain cancer. The FDA has also granted Breakthrough Device designation for the NSCLC treatment. Insightec plans to launch the LIMITLESS study to assess the clinical benefit of using noninvasive, low-intensity focused ultrasound combined with systemic immunotherapy in the treatment of patients with brain metastases from lung cancer.
InvestmentExpand
growth-positive
Israeli med tech firm bullish on China's healthcare
Israeli medical technology company Insightec is increasing its investment in Chinas healthcare industry, recognizing the countrys growth potential and favorable business environment. Insightec plans to cooperate with top medical institutions in China to develop treatment methods suitable for Chinese patients. The companys opportunities in Israel are limited compared to Chinas larger market. Insightec focuses on the research and development of magnetic resonance-guided focused ultrasound systems for various medical conditions. It has already collaborated with over 200 medical institutions globally, including more than 30 hospitals in China. Insightec acknowledges Chinas potential and advancement in medical research and healthcare services through its partnerships with Chinese hospitals. China and Israel have strengthened cooperation in innovation, with the China-Israel Changzhou Innovation Park serving as a platform for collaboration. The bilateral trade and economic relations between China and Israel have grown significantly over the past 30 years.
PartnersInvestment
growth-negative
Insightec cuts SPAC merger valuation
Israeli medical device company Insightec is facing a lower valuation for its planned SPAC merger due to market conditions. Elbit Medical, a shareholder in Insightec, reported that the merger will proceed at a lower valuation than previously reported. Insightec has developed a device for minimally invasive surgery based on ultrasound. The SPAC merger trend has slowed down in the market, with disappointment in the performance of companies and stricter regulatory requirements. Insightec is controlled by Koch Disruptive Technologies (KDT), which has invested $200 million for a 40% stake. Insightec recently received FDA clearances for treating Parkinsons disease and prostate growths. The companys revenue is growing, but it still reports large losses.
Public Trading
growth-positive
Medical device co Insightec set for SPAC merger at $2b valuation
Israeli medical device company Insightec is in advanced talks to merge with a SPAC company and list on Wall Street with a company valuation of $2 billion. Insightec has developed a device for minimally invasive surgery based on ultrasound. The CEO has previously mentioned the potential for an exit worth tens of billions of dollars. Insightec is currently controlled by KDT, which has invested $200 million for a 40% stake. In the first half of 2021, the company reported revenue of $27 million and a net loss of $31 million. The SPAC merger would provide Insightec with extra funding through a PIPE investment.
Public TradingInvestment
growth-negative
זיסר חלם על אינסייטק בשווי מיליארד דולר - בלנק וקרן יורק הגשימו
American investment fund York recently sold 7% of medical company Insightec for $70 million. The sale was made at a lower value than the $1.3 billion at which it valued a $150 million fundraising. However, York has returned its full investment in Insightec and remains with shares worth $150 million.
InvestmentAcquisition
growth-positive
Insightec Announces Positive Coverage Decision By Aetna For MR-guided Focused Ultrasound To Treat Essential Tremor
Insightec announced that Aetna is the first national payor to cover MR-guided Focused Ultrasound for treating medication-refractory Essential Tremor. This expands patient access to non-Medicare patients. Essential Tremor affects an estimated ten million Americans, and many patients do not get satisfactory relief from available medications. Focused ultrasound treatment is performed in a single outpatient procedure with immediate improvement of tremor in the treated hand. Insightec has more than 60 Treatment Centers worldwide using their Exablate Neuro platform. Medicare covers the treatment in all 50 states, and it is also covered by 30 independent Blue Cross Blue Shield Association plans and nine private payors.
Customers
growth-positive
Philips & Insightec join forces to usher in the future of patient care
InSightec, an Israeli MedTech company, has announced a collaboration with Royal Philips, a multinational leader in health technology, to expand access to MR-guided Focused Ultrasound. InSightecs Exablate Neuro uses focused acoustic energy to treat deep in the brain without incisions or implants. The collaboration aims to increase adoption of InSightecs technology and transform patient care. Market introduction for the compatible systems is expected in 2023. InSightec has recently achieved several milestones, including a $150 million funding round, national healthcare reimbursements in Japan and England, and this collaboration with Royal Philips.
Partners
growth-positive
INSIGHTEC Announces MR-guided Focused Ultrasound to Treat Essential Tremor Received Funding by National Health Service (NHS) England
INSIGHTEC announced that the National Health Service (NHS) England has approved funding for MR-guided Focused Ultrasound for the treatment of medication-refractory Essential Tremor patients. This approval is a major breakthrough for patients who do not get satisfactory relief from medications. MR-guided Focused Ultrasound uses high intensity sound waves to target and treat the area of the brain responsible for the tremor. The treatment is incisionless and often results in immediate relief. INSIGHTEC is a global healthcare company focused on the therapeutic power of acoustic energy.
Customers
growth-positive
Israeli company leads first-ever incisionless focused ultrasound treatment for Parkinson's in Japan
Israeli MedTech company INSIGHTEC has received the first-ever national reimbursement and approval for focused ultrasound treatment for Parkinsons Disease from the Japanese Ministry of Health. The reimbursement signifies a major milestone for patients with Parkinsons Disease in Japan. INSIGHTECs FDA approved product, Exablate Neuro, provides an incisionless treatment by using ultrasound waves to target and ablate tissue deep within the brain. The treatment option is now covered by the National Health Insurance in Japan, providing a new option for Parkinsons Disease patients. INSIGHTEC is headquartered in Haifa, Israel and has offices in Miami, Dallas, Shanghai, and Tokyo.
Customers
growth-positive
INSIGHTEC MR-Guided Focused Ultrasound Receives Reimbursement from Japanese Ministry of Health, Labour and Welfare for the Treatment of Parkinson's Disease
INSIGHTEC, a global medical technology company, has announced that it has received national reimbursement from the Japanese Ministry of Health, Labour and Welfare for treating Parkinsons Disease. The companys Exablate Neuro uses focused ultrasound waves to target and ablate tissue deep within the brain with no incisions. The treatment is performed under Magnetic Resonance Imaging (MRI) guidance for real-time treatment monitoring. The Exablate Neuro device received approval for the treatment of medication-refractory essential tremor and National Health Insurance coverage in June 2019 and received a pre-market approval for the treatment of Parkinsons Disease in January 2020.
CustomersExpand
growth-positive
INSIGHTEC's MR-Guided Focused Ultrasound Treatment for Essential Tremor Receives Complete Medicare Coverage in the US
INSIGHTEC has achieved complete Medicare coverage across all 50 states for MR-guided focused ultrasound treatment of medication-refractory Essential Tremor. This milestone allows millions of people to access the incisionless treatment option. INSIGHTECs Exablate Neuro platform, which delivers ultrasound waves to ablate target tissue without incisions, has been FDA-approved since 2016 for the treatment of Essential Tremor. The company has worked closely with the seven Local Medicare Administrative Contractors to secure positive coverage decisions. In addition to Medicare, 22 independent Blue Cross Blue Shield Association plans also offer focused ultrasound treatment for Essential Tremor. INSIGHTEC is a global medical technology innovator headquartered in Haifa, Israel, and Miami, Florida.
Customers
growth-positive
INSIGHTEC Investment Up to $150 Million Led by Koch Disruptive Technologies
INSIGHTEC, a commercial-stage medical technology company, has announced a Series F investment round of up to $150 million at a post-money valuation of $1.3 billion. The round is being led by Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, which has committed to invest $100 million. This is KDTs second direct investment in INSIGHTEC. The funds will be used to support continued research into focused ultrasound to treat certain movement disorders in patients suffering from essential tremor and tremor-dominant Parkinsons disease.
Investment
growth-positive
Charles Koch to invest $200-250m in Insightec
Koch Industries, controlled by billionaire Charles Koch, is expected to invest $200-250 million in Israeli MRI guided ultrasound company Insightec and become the controlling shareholder. The deal reflects a valuation of $710-720 million for Insightec. Prior to the deal, Koch Industries already held a 17% stake in Insightec. In addition, Insightec has signed a non-binding Memorandum of Understanding with one of its existing shareholders to invest an additional $100-150 million. Insightec developed and markets a system for using focused MRI-guided ultrasound waves for medical treatments.
Investment
growth-positive
Koch seen as the investor injecting $150m into Insightec
Insightec, a MRI guided ultrasound company, has signed a non-binding memorandum of understanding with an existing shareholder for an additional investment of $100-150 million. The investor is likely Koch Industries, which previously led a $150 million investment in Insightec. Insightec reported a 10% increase in revenue and a 19% increase in net loss in the first nine months of 2019. Elbit Medical, which holds 18% of Insightec, and Elbit Imaging, the parent company, have signed a non-binding MOU for the sale of their investment in Insightec to repay their bond debt. Elbit Medicals stake in Insightec is set to fall to 3.1%.
Investment
growth-positive
Elbit Medical agrees to sell Insightec stake for $102m
Elbit Medical is selling most of its stake in Insightec, an Israeli MRI-guided ultrasound company, for $102 million at a company valuation of $702 million. The sale is contingent on shareholders approval. Elbit Medical will use the payment to repay NIS 185 million on its Series C bonds and buy back the companys shares. Insightec developed a system for using focused MRI-guided ultrasound waves for medical treatments.
Acquisition
growth-negative
Elbit Medical signs MoU to sell Insightec stake for $128m
Elbit Medical Technologies has signed a memorandum of understanding to sell most of its shares in Insightec. The sale is valued at $128.4 million, representing a company valuation of $720 million. The designated buyer is negotiating an investment in Insightec and the purchase of stakes from other shareholders. Elbit Medical will use the proceeds to repay its debt. Elbit Imaging, the parent company of Elbit Medical, also signed a non-binding MOU for a separate deal to sell its entire direct holding in Insightec for $1.2 million. The deals are expected to have a negative impact on Elbit Medicals growth.
AcquisitionInvestment
growth-positive
Insightec wants to usher in a new era of incisionless surgery
Israeli company Insightec is developing an outpatient procedure using its Exablate Neuro focused ultrasound device to treat essential tremor. The device uses concentrated sound waves to thermally ablate the thalamus, reducing hand tremors. Insightec has received FDA approval for the device and has treated around 2,000 tremor patients in the US. The company has also made progress in its reimbursement strategy, with coverage from Medicare and 18 Blue plans. Insightec has raised over $400 million in funding, including a $150 million Series E round led by Koch Disruptive Technologies. The company aims to install 300 or more systems in the US over the next decade. Insightec is also exploring other neurological conditions and potential applications for its technology, such as targeted drug delivery and breaking down the blood-brain barrier.
Customers
growth-positive
INSIGHTEC MR-Guided Focused Ultrasound Receives Reimbursement from Japanese Ministry of Health, Labour and Welfare for the Treatment of Essential Tremor
INSIGHTEC has received national reimbursement from the Japanese Ministry of Health, Labour and Welfare for treating essential tremor using their incisionless surgery technology. The reimbursement validates the use of focused ultrasound technology and allows INSIGHTEC to expand availability of their treatment globally. Essential tremor is a common movement disorder that affects millions of people worldwide. INSIGHTECs Exablate Neuro device received approval in Japan in 2016 and is currently being used in nine medical institutions in the country.
Customers
growth-positive
Israeli startup uses ultrasound waves to reduce Parkinson's tremors
Israeli startup Insightec has developed a non-invasive technology called Exablate Neuro that helps alleviate the symptoms of Essential Tremor and Parkinsons disease. The treatment uses high-intensity focused ultrasound beams and magnetic resonance imaging to target and ablate the affected areas of the brain. Insightec has obtained FDA approvals for its technology and has treated over 2,000 neuro-patients in more than 50 medical centers worldwide. The company has raised $307 million in funding from investors including GE Healthcare and VP Koch Disruptive Technologies.
Customers
growth-positive
INSIGHTEC Announces Expansion of Positive Insurance Coverage for MR-guided Focused Ultrasound to Treat Essential Tremor
INSIGHTEC announced that Noridian has posted a positive Local Coverage Determination for MR-guided focused ultrasound (MRgFUS) effective April 1, 2019. Medicare beneficiaries in 38 US states will now have coverage for the incisionless treatment for essential tremor that has not responded to medication.
Customers
growth-positive
INSIGHTEC Announces FDA Approval of Exablate Neuro for the Treatment of Tremor-Dominant Parkinson's Disease
INSIGHTEC has received FDA approval to expand the indication of its Exablate Neuro device to include the treatment of patients with tremor-dominant Parkinsons disease. The device uses focused ultrasound for incisionless thalamotomy guided by MR imaging. This approval allows INSIGHTEC to provide more treatment options for Parkinsons patients, improving their quality of life. The approval was based on data from a study conducted at the University of Virginia School of Medicine and the Swedish Neuroscience Institute. INSIGHTEC is a global medical technology innovator headquartered in Haifa, Israel, and Miami, Florida.
Customers
growth-positive
InSightec receives CE Mark for Exablate Neuro for Siemens Healthineers MRI scanners
Siemens Healthineers and InSightec have announced the CE clearance of Exablate Neuro compatible with Magnetom Skyra, Prisma and Prisma Fit scanners from Siemens Healthineers. The MRI compatibility holds potential to expand patient access to incisionless brain surgery. The CE mark includes approval for treatment of medication-refractory essential tremor, tremor-dominant Parkinson’s disease, and neuropathic pain. Clínica Universidad de Navarra in Spain is the first institution in Europe to successfully treat patients with Exablate Neuro compatible with MRI scanners from Siemens Healthineers.
CustomersPartners
growth-positive
Insightec CEO confident of $30-50 billion exit
Insightec, an Israeli medical device company, has seen a positive turnaround in recent years, with a 50% growth in revenue between 2016 and 2017 and continued growth projected in 2018. The companys success is attributed to large investments, product approval for treatment of essential tremor, and the recruitment of CEO Maurice Ferré. Insightec has received $62 million from York Capital and $150 million in a financing round led by Koch Disruptive Technologies. The company is expanding its partnerships from GE to also include Siemens, and is preparing to enter the Chinese market.
InvestmentExpand
growth-positive
INSIGHTEC's MR-Guided Focused Ultrasound Treatment for Essential Tremor Now Covered By Medicare in 25 States
INSIGHTEC, a medical technology innovator, has announced that Medicare benefit coverage has been expanded for the treatment of essential tremor using MR-guided focused ultrasound. This expansion brings the total number of states with coverage for the Neuravive treatment to 25. The announcement is seen as a positive growth for the company, as it allows a growing number of patients to have affordable access to the treatment. The coverage is available in various states across the United States, and INSIGHTEC looks forward to achieving coverage for all Medicare patients in the near future.
Customers
growth-positive
FDA approves Insightec-Siemens neurology surgery platform
Insightec, a company in which Elbit Medical Technologies holds a 22% stake, has obtained FDA marketing approval for its brain surgery product developed jointly with Siemens. This product has been adopted for use with Siemenss imaging devices. The exclusive agreement between Insightec and GE was opened in 2016, but a joint development agreement with Siemens was signed at the same time. Insightecs revenue is projected to grow in 2018 with the launch of Siemenss product. The company hopes to expand its business by attaining medical insurance reimbursement for users of its product in additional states in the US and in other countries, and by extending the capabilities of the device to tremors from Parkinsons Disease and improved delivery of drugs to the brain.
PartnersCustomers
growth-positive
INSIGHTEC Receives FDA Approval to Initiate Clinical Study of MR-Guided Focused Ultrasound to Treat Patients With Alzheimer's Disease
INSIGHTEC has received FDA approval to initiate a clinical study using its MR-guided Focused Ultrasound to treat patients with Alzheimers disease. The study aims to evaluate the safety and efficacy of using INSIGHTECs technology to disrupt the blood brain barrier in patients diagnosed with AD. The company has previously conducted a trial on five patients with early stage AD, which showed promising results. INSIGHTEC is a global medical technology innovator headquartered in Haifa, Israel, and Miami, Florida.
Customers
growth-positive
Insightec logs Medicare win for MR-guided focused ultrasound in treating essential tremor
Insightec has won Medicare benefit coverage for its MR-guided focused ultrasound system for the treatment of essential tremor in six new states. This brings the total number of states with Medicare coverage for Insightecs technology to 16. The companys system will now be covered under Medicare in Indiana, Iowa, Kansas, Nebraska, Michigan, and Missouri. Additional Medicare Administrative Contractors have also issued positive Draft Local Coverage Determinations, potentially increasing the total number of states to 38. Insightecs MRgFUS system is used by eleven medical centers in the U.S. to treat essential tremor patients. The coverage expansion will allow more patients to access the incisionless focused ultrasound treatment for essential tremor.
Customers
growth-positive
US Medicare to reimburse for Insightec tremor treatment
Israeli company Insightec experienced a 28% growth in revenue in 2017. The US Centers for Medicare & Medicaid Services (CMS) has agreed to provide reimbursement for Insightecs device, which treats essential tremor. Insightecs revenue has been steadily increasing, reaching $32 million in 2017. The company has also entered a multi-center trial for the treatment of movement disorders resulting from Parkinsons Disease. Insightec recently signed a partnership agreement with Siemens to market its products, in addition to its existing partnership with GE. The company plans to expand its devices capabilities to treat other neurological diseases. Elbit Medical Technologies holds a 22% stake in Insightec.
CustomersPartners
growth-positive
First Parkinson's Patient Treated with Insightec's Incisionless...
Insightec has treated its first patient in a pivotal study of its non-invasive ultrasound therapy, ExAblate Neuro, for advanced Parkinsons patients who have not responded to medication. The device uses focused ultrasound and MRI to destroy a target deep in the brain responsible for causing Parkinsons tremors. The therapy aims to improve motor function and treat involuntary movements of arms and legs. Insightec plans to recruit a total of 40 participants and expects to complete the research by December 2020. The company has also begun a parallel Phase 3 trial of its MRI-guided focused ultrasound system for treating motor symptoms in Parkinsons.
CustomersExpand
growth-positive
INSIGHTEC Closes $150 Million Series E Financing
INSIGHTEC, a medical technology company, has closed a $150 million Series E private equity investment round led by Koch Disruptive Technologies. The company plans to use the funding to support marketing and commercialization for its approved treatments and for further research and development. INSIGHTECs Exablate Neuro is the first focused ultrasound device approved by the FDA to treat essential tremor. The company aims to transform the lives of millions of patients with its incisionless solutions. Existing investors in INSIGHTEC include Elbit Imaging, York Capital, Exigent Capital Group, GE Healthcare, GEOC, and Meditech Advisors.
Investment
growth-positive
Insightec, Virginia Tech collab on focused ultrasound brain disorder R&D
Insightec has partnered with the Virginia Tech Carilion Research Institute to develop treatments for brain disorders using their Exablate Neuro focused ultrasound device. The treatments will also utilize Siemens magnetic resonance imaging devices. The partnership aims to develop safe and efficacious protocols for treating cancer, brain tumors, disruptions of the blood-brain barrier, and neuromodulation for psychiatric disorders. Insightec recently raised $150 million in a Series E round of financing led by Koch Industries Koch Disruptive Technologies to support its MRI-guided focused ultrasound technologies.
Partners
Growth-Positive
Koch Disruptive Technologies to Lead $150 Million Investment of INSIGHTEC
Koch Disruptive Technologies, a subsidiary of Koch Industries, has led a $150 million Series E funding round for INSIGHTEC, a medical device company that uses MRI-guided focused ultrasound for surgery. The investment will allow INSIGHTEC to further commercialize its approved indications and continue research in areas such as Parkinsons disease, Alzheimers disease and brain tumors. This is the first investment for Koch Disruptive Technologies since it commenced operations in November 2017.
Investment
growth-positive
Koch Industries leading $75-150m round in Insightec
Insightec, an Israeli medical equipment company, has secured an investment of between $75m and $150m from Koch Industries, owned by Charles and David Koch. The investment values Insightec at $460m. The company, which was founded in 1999, develops, manufactures and markets medical systems used for non-invasive treatment of internal tumours. The new investment will allow Insightec to continue operating for between two and five more years.
Investment
growth-positive
INSIGHTEC's Exablate Neuro Named Best Medical Technology at Esteemed Prix Galien Awards 2017
INSIGHTEC has been awarded Best Medical Technology for Exablate Neuro by The Galien Foundation. The award confirms INSIGHTECs dedication to non-invasive medical treatment and their commitment to improving the lives of patients with essential tremor. The U.S. FDA approved Exablate Neuro for the non-invasive treatment of essential tremor patients. INSIGHTEC is the world leader in MR-guided Focused Ultrasound (MRgFUS) and their platforms, Exablate and Exablate Neuro, are proven technology for treating essential tremor, painful bone metastases, and uterine fibroids.
Customers
growth-positive
New Ultrasound Treatment Could Be An Alternative to Brain Surgery For Essential Tremors
Insightec, an Israeli company, has received FDA approval for their ultrasound device, Exablate Neuro, which can treat essential tremor in patients not responding to medication. The device uses MRI and focused ultrasound waves to dissolve or remove targeted tissue in the brain. This non-invasive treatment provides a safe and scalpel-free approach to a debilitating neurological disease. The New England Journal of Medicine published a study showing the effectiveness of the treatment in reducing tremors. Insightec aims to expand the availability of the technology to more medical centers globally.
Customers
growth-positive
Israeli ultrasound developer Insightec raises $22m
Israeli ultrasound developer Insightec has raised $22 million in Series D financing from current shareholders. The company has developed MR-guided Focused Ultrasound (MRgFUS), a non-invasive therapy platform used in neurosurgery, oncology, and gynecology. Insightec has appointed Dr. Maurice R. Ferré as CEO, while the company founder, Dr. Kobi Vortman, takes a seat on the board. Insightec offers clinical applications in Womens Health, Oncology, and Neurosurgery, and holds over 90 patents and regulatory approvals.
InvestmentManagement Changes
Insightec Team
Employee Info
| Employees (range) | 201-500 |
| Exact count | 499 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Insightec Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 512755745 |
| Crunchbase | insightec |
| Phone | +97248131313 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-10-30T00:00:00.000Z |
| Created | 2014-07-17T00:00:00.000Z |